Synapse - Michael Mauro

Search Within

Michael John Mauro

Results (276)

Safety and efficacy of combined ruxolitinib and thalidomide in patients with myelofibrosis: A phase II study

Meeting Abstract

Rampal, R. K.; Verstovsek, S.; Devlin, S. M.; King, A. C.; Stein, E. M.; Pemmaraju, N.; Mauro, M. J.; Kadia, T. M.; Montalban-Bravo, G.; Alvarez, K.; more...
Blood (2019)

Fulltext@MSK | Save

Cardiovascular (CV)-related hospitalizations and associated costs among US patients in simplicity: An observational study of patients with chronic-phase chronic myeloid leukemia (CP-CML) in routine clinical practice

Meeting Abstract

Goldberg, S. L.; Mauro, M. J.; Cortes, J. E.; Keating, S. J.; Bhandari, H.; Chen, C.
Blood (2019)

Fulltext@MSK | Save

Phase 1 trial of K0706, a novel oral BCR-ABL1 tyrosine kinase inhibitor (TKI): In patients with chronic myelogenous leukemia (CML) and phildelphia positive acute lymphoblastic leukemia (Ph + ALL) failing ≥ 3 prior TKI therapies: Initial safety and efficacy

Meeting Abstract

Cortes, J. E.; Kim, D. W.; Nicolini, F. E.; Saikia, T.; Charbonnier, A.; Apperley, J. F.; Rathnam, K.; Deininger, M. W.; De Lavallade, H.; Khattry, N.; more...
Blood (2019)

Fulltext@MSK | Save

Cytogenetic and molecular response with first- and second-generation tyrosine kinase inhibitor (TKI) therapy in simplicity: An observational study of patients with chronic-phase chronic myeloid Leukemia (CP-CML)

Meeting Abstract

Cortes, J. E.; Chen, C.; Davis, C.; Goldberg, S. L.; Mauro, M. J.
Blood (2019)

Fulltext@MSK | Save

Patient-reported outcome results from the US Life after Stopping TKIs (LAST) study in patients with chronic myeloid leukemia

Meeting Abstract

Flynn, K. E.; Weinfurt, K. P.; Lin, L.; Radich, J. P.; Schiffer, C. A.; Mauro, M. J.; Ibarz, J. P.; Moore, J. O.; Larson, R. A.; Oehler, V. G.; more...
Blood (2019)

Fulltext@MSK | Save

Pregnancy management in cml patients: to treat or not to treat? Report of 224 outcomes of the European Leukemia Net (ELN) database

Meeting Abstract

Abruzzese, E.; Turkina, A. G.; Apperley, J. F.; Bondanini, F.; de Fabritiis, P.; Kim, D. W.; Dyagil, I.; Ganeva, P.; Garcia-Gutierrez, V.; Kazakbaeva, K.; more...
Blood (2019)

Fulltext@MSK | Save

Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure

Journal Article

Hughes, T. P.; Mauro, M. J.; Cortes, J. E.; Minami, H.; Rea, D.; DeAngelo, D. J.; Breccia, M.; Goh, Y. T.; Talpaz, M.; Hochhaus, A.; more...
New England Journal of Medicine (2019)

Fulltext@MSK | Save

A multicenter, randomized phase III study of asciminib (ABL001) versus bosutinib in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) previously treated with ≥2 tyrosine kinase inhibitors (TKIs)

Meeting Abstract

Mauro, M. J.; Hochhaus, A.; Boquimpani, C.; Minami, Y.; Allepuz, A.; Polydoros, F.; Bédoucha, V.; Aimone, P.; Réa, D.
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

Rates of deep molecular response by digital and conventional PCR with frontline nilotinib in newly diagnosed chronic myeloid leukemia: A landmark analysis

Journal Article

Berdeja, J. G.; Heinrich, M. C.; Dakhil, S. R.; Goldberg, S. L.; Wadleigh, M.; Kuriakose, P.; Cortes, J.; Radich, J.; Helton, B.; Rizzieri, D.; more...
Leukemia and Lymphoma (2019)

Fulltext@MSK | Save

Combination of asciminib+nilotinib or asciminib+dasatinib in previously treated chronic myeloid leukemia (CML) patients: Phase 1 study results

Meeting Abstract

DeAngelo, D. J.; Mauro, M. J.; Kim, D. W.; Cortes, J.; Réa, D.; Hughes, T. P.; Minami, H.; Breccia, M.; Talpaz, M.; Hochhaus, A.; more...
Clinical Lymphoma, Myeloma and Leukemia (2019)

Fulltext@MSK | Save